Ionis Pharmaceuticals has been granted a patent for compounds and methods to reduce LRRK2 RNA and protein levels in cells, potentially ameliorating symptoms of neurodegenerative diseases like Parkinson’s. The patent includes a modified oligonucleotide with a specific chemical structure. GlobalData’s report on Ionis Pharmaceuticals gives a 360-degree view of the company including its patenting strategy. Buy the report here.

Smarter leaders trust GlobalData


Premium Insights Ionis Pharmaceuticals Inc - Company Profile

Buy the Report

Premium Insights

The gold standard of business intelligence.

Find out more

According to GlobalData’s company profile on Ionis Pharmaceuticals, Nucleic acid active pharmaceutical ingredient was a key innovation area identified from patents. Ionis Pharmaceuticals's grant share as of January 2024 was 38%. Grant share is based on the ratio of number of grants to total number of patents.

A recently granted patent (Publication Number: US11873495B2) discloses a series of claims related to modified oligonucleotides, oligomeric compounds, pharmaceutical compositions, and methods for treating Parkinson's disease. The patent covers modified oligonucleotides with specific chemical structures, including those in sodium or potassium salt form, and populations of stereorandom phosphorothioate internucleoside linkages. Pharmaceutical compositions containing these modified oligonucleotides, along with pharmaceutically acceptable diluents or carriers like phosphate-buffered saline or artificial cerebrospinal fluid, are also claimed.

Furthermore, the patent outlines methods for administering the pharmaceutical compositions to subjects for treating Parkinson's disease, reducing the expression of LRRK2 in cells, and ameliorating symptoms like ataxia, neuropathy, and aggregate formation associated with the disease. The methods involve utilizing the disclosed modified oligonucleotides and oligomeric compounds in the compositions, with a focus on human subjects. Overall, the patent provides a comprehensive framework for potential therapeutic interventions targeting Parkinson's disease through the modulation of LRRK2 expression and associated symptoms, backed by specific chemical structures and pharmaceutical formulations outlined in the claims.

To know more about GlobalData’s detailed insights on Ionis Pharmaceuticals, buy the report here.

Premium Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies